{"schema_version":"1.0","type":"article","title":"$130 Billion in Six Months: Big Pharma Is Buying Time","url":"https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1-en.md","lang":"en","date":"2026-08-10","publish_at":"2026-08-10T08:00:00+08:00","updated_at":"2026-08-10","category":"商業分析系列","topic":"商業分析系列","tags":["biopharma M&A","pharma acquisitions","patent cliff","Eli Lilly","Merck","AbbVie","Gilead","GSK","IQVIA","biotech"],"summary":"Biopharma M&A reached approximately $130 billion in the first half of 2026 as buyers favored late-stage and near-launch assets. This is not a broad biotech bull market; it is Big Pharma using cash and contingent deal structures to buy measurable development time before the patent cliff.","key_points":[],"facts":[],"sections":["01 | The 52-Deal and 42-Deal Totals Use Different Methodologies","02 | As the Patent Clock Runs Down, Drugmakers Buy Clinical Time","03 | Lilly Is Shopping Aggressively, but Integration and Attrition Are the Real Tests","04 | Gilead and GSK Are Betting on Oncology Assets Closer to Commercialization","05 | Even One of the Largest Deals Cannot Be Read from the Headline Value Alone","06 | The M&A Recovery Illuminates Only a Small Group of Biotechs","07 | What Should Readers in Taiwan Watch?","Conclusion | A Hundred-Billion-Dollar Half-Year Spent on Time","References","Disclaimer"],"references":[{"title":"Verified through July 19, 2026.","source":"","date":"","url":""},{"title":"[BioSpace, H1 2026 M&A count and methodology]","source":"","date":"","url":"https://www.biospace.com/business/biopharma-strikes-50-m-as-deals-in-h1-led-by-lillys-25b-spend"},{"title":"[IQVIA, Biopharma M&A: Mid-year 2026 update]","source":"","date":"","url":"https://www.iqvia.com/locations/emea/blogs/2026/07/biopharma-ma-mid-year-2026-update"},{"title":"[PwC, US Deals 2026 midyear outlook]","source":"","date":"","url":"https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html"},{"title":"[Merck/Terns transaction agreement]","source":"","date":"","url":"https://www.merck.com/news/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml/"},{"title":"[Merck completion of Terns acquisition]","source":"","date":"","url":"https://www.merck.com/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc/"},{"title":"[AbbVie/Apogee transaction announcement]","source":"","date":"","url":"https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-apogee-therapeutics-deepening-immunology"},{"title":"[Gilead completion of Arcellx acquisition]","source":"","date":"","url":"https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel"},{"title":"[Gilead completion of Tubulis acquisition]","source":"","date":"","url":"https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Completes-Acquisition-of-Tubulis-Further-Strengthening-Oncology-Portfolio/default.aspx"},{"title":"[GSK/Nuvalent transaction agreement]","source":"","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/"},{"title":"[GSK completion of Nuvalent acquisition]","source":"","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/"},{"title":"[Sun Pharma/Organon definitive agreement]","source":"","date":"","url":"https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/"}],"images":[{"alt":"Lilly leads as large drugmakers spend 130 billion dollars in six months to buy time","url":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1-en/figure-01.png"},{"alt":"Different BioSpace and IQVIA methodologies for biopharma M&A in the first half of 2026","url":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1-en/figure-03.png"},{"alt":"How the patent cliff drives large drugmakers to acquire clinical-stage assets and save development time","url":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1-en/figure-02.png"},{"alt":"An announced deal value must be separated into upfront cash, equity value, enterprise value, CVRs, milestones and closing conditions","url":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-10）。$130 Billion in Six Months: Big Pharma Is Buying Time。https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-10-biopharma-ma-buying-time-2026h1.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}